UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (10), p.2899-2909

2021

Volltextzugriff (PDF)

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO clinical and research reports, 2021-07, Vol.2 (7), p.100187-100187, Article 100187

2021

Volltextzugriff (PDF)

Decade in review: a new era for RET-rearranged lung cancers

Translational lung cancer research, 2020-12, Vol.9 (6), p.2571-2580

2020

Volltextzugriff (PDF)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO clinical and research reports, 2023-08, Vol.4 (8), p.100546, Article 100546

2023

Volltextzugriff (PDF)

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Clinical cancer research, 2021-05, Vol.27 (10), p.2920-2927

2021

Volltextzugriff (PDF)

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

Journal of clinical oncology, 2016-06, Vol.34 (18), p.2165-2171

2016

Volltextzugriff (PDF)

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Journal of thoracic oncology, 2023-09, Vol.18 (9), p.1222-1232

2023

Volltextzugriff (PDF)

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.463-475

2023

Volltextzugriff (PDF)

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Cancer cell, 2021-07, Vol.39 (7), p.897-899

2021

Volltextzugriff (PDF)

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

Clinical cancer research, 2022-11, Vol.28 (21), p.4649-4659

2022

Volltextzugriff (PDF)

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center

Oncotarget, 2019-10, Vol.10 (56), p.5817-5823

2019

Volltextzugriff (PDF)

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer

European urology focus, 2016-10, Vol.2 (4), p.445-452

2016

Volltextzugriff (PDF)

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

JCO precision oncology, 2021, Vol.5

2021

Volltextzugriff (PDF)

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3062-3062

2023

Volltextzugriff (PDF)

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21146-e21146

2023

Volltextzugriff (PDF)

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR- mutant lung cancers

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9100-9100

2022

Volltextzugriff (PDF)

Genomic characterization of FGFR -altered solid tumors using a clinically annotated pan-cancer repository

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3074-3074

2023

Volltextzugriff (PDF)

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3073-3073

2023

Volltextzugriff (PDF)

Imaging with 89ZrZr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

The lancet oncology, 2024-08, Vol.25 (8), p.1015

2024

Volltextzugriff (PDF)

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

The lancet oncology, 2024-08, Vol.25 (8), p.1015-1024

2024

Volltextzugriff (PDF)

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3002-3002

2023

Volltextzugriff (PDF)

Abstract 3697: High PD-L1 expression and targetable mutations occur independently in NSCLC and are not influenced by smoking or race

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3697-3697

2018

Volltextzugriff (PDF)

Mechanisms of acquired resistance to TRK inhibitors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3104-3104

2022

Volltextzugriff (PDF)

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1 -rearranged lung cancers

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9049-9049

2021

Volltextzugriff (PDF)

Abstract 1394: Comprehensive clinical and genomic analysis for patients with MYC , MYCN , and MYCL amplified solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1394-1394

2023

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Oncology
(12)
Humans
(10)
Respiratory System
(5)
Aged
(4)
Aged, 80 And Over
(4)
Erbb Receptors - Genetics
(4)
Female
(4)
Lung Neoplasms - Drug Therapy
(4)
Male
(4)
Middle Aged
(4)
Adult
(3)
Lung Neoplasms - Genetics
(3)
Lung Neoplasms - Pathology
(3)
Mutation
(3)
Original Reports
(3)
Protein Kinase Inhibitors - Therapeutic Use
(3)
Targeted Therapies
(3)
Alleles
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

Decade in review: a new era for RET-rearranged lung cancers

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center

Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets)

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR- mutant lung cancers

Genomic characterization of FGFR -altered solid tumors using a clinically annotated pan-cancer repository

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

Imaging with 89ZrZr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer

Abstract 3697: High PD-L1 expression and targetable mutations occur independently in NSCLC and are not influenced by smoking or race

Mechanisms of acquired resistance to TRK inhibitors

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1 -rearranged lung cancers

Abstract 1394: Comprehensive clinical and genomic analysis for patients with MYC , MYCN , and MYCL amplified solid tumors

Suchergebnisse filtern